Decreased tumorigenesis in mice with a Kras point mutation at C118
[Paper-level Aggregated] PMCID: PMC4234187
Evidence Type(s): Oncogenic, Functional, Predictive, Prognostic
Justification: Oncogenic: The introduction of the C118S mutation into the Kras gene was shown to affect tumorigenesis, specifically leading to fewer lung tumors in Kras+/C118S and KrasC118S/C118S mice when treated with the carcinogen urethane, indicating a role in oncogenic processes. Functional: The study demonstrated that the C118S mutation alters the function of the Kras protein, as it specifically blocks redox-dependent reactions that lead to Ras activation, impacting downstream signaling pathways such as the MAPK pathway. Predictive: The presence of the C118S mutation was associated with a reduced tumor burden and a shift towards smaller tumors in mice, suggesting that this mutation can predict a lower likelihood of tumor development in response to carcinogenic exposure. Prognostic: The findings indicate that mice with the C118S mutation have a different tumorigenic outcome compared to those with wild-type Kras, which could be used to prognosticate the progression and severity of lung tumors in a carcinogen-induced model.
Gene→Variant (gene-first): NOS2(4843):C118 NOS2(4843):C118S KRAS(3845):G13D NRAS(4893):Q61L NOS2(4843):G353 transversion to C NOS2(4843):G353>C NOS2(4843):cysteine 118 KRAS(3845):G12D NOS3(4846):S1177D KRAS(3845):Q61R/L NRAS(4893):Q61R
Genes: NOS2(4843) KRAS(3845) NRAS(4893) NOS3(4846)
Variants: C118 C118S G13D Q61L G353 transversion to C G353>C cysteine 118 G12D S1177D Q61R/L Q61R